倪雅琼,Jiangqin Liu,Youxin Tian. Clinical value of cancer cells joint detection in peripheral blood plasma of thyroid cancer patients. Oncol Transl Med, 2014, 13: 518-522.
Clinical value of cancer cells joint detection in peripheral blood plasma of thyroid cancer patients
Received:September 24, 2014  Revised:November 07, 2014
View Full Text  View/Add Comment  Download reader
KeyWord:thyroid cancer; flow cytometry; circulating tumor cells; cytokeratin; polymorphic epithelial mucin
Author NameAffiliationPostcode
倪雅琼 Department of Head-neck Surgical Oncology, Tumor Hospital of Gansu Province, Lanzhou 730050, China 730050
Jiangqin Liu Department of Head-neck Surgical Oncology, Tumor Hospital of Gansu Province, Lanzhou 730050, China 730050
Youxin Tian Department of Head-neck Surgical Oncology, Tumor Hospital of Gansu Province, Lanzhou 730050, China 
Hits: 7813
Download times: 8487
Abstract:
      Objective: We aimed to detect cytokeratin 19 (CK19) and polymorphic epithelial mucin 1 (MUC1) expression in peripheral blood of thyroid cancer patients, and investigate the clinical value of it as a diagnostic marker for circulating blood micrometastases. Methods: The flow cytometry (FCM) was used to detect and analyze CK19 and MUC1-expressing cells in peripheral blood of 491 thyroid cancer patients. Results: CK19 and MUC1 expression showed no statistically significant difference with gender and age in thyroid cancer patients (P > 0.05), while had statistically significant difference with tumor size, lymph node stage and distant metastasis (P < 0.01). The expression of CK19 and MUC1 were positively correlated (r = 0.628, P = 0.00). Conclusion: CK19 is closely related to MUC1 expression, tumor size, extent of invasion and distant metastasis in peripheral blood of thyroid cancer patients. The circulating blood CK19 and MUC1 tests can help predict thyroid cancer micrometastases and prognosis.
Close